A Study of TRK-950 in Patients With Advanced Solid Tumors
NCT05423262
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
49
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Melanoma
Interventions
BIOLOGICAL:
TRK-950
BIOLOGICAL:
TRK-950
BIOLOGICAL:
TRK-950
DRUG:
Nivolumab
BIOLOGICAL:
TRK-950
Sponsor
Toray Industries, Inc